Back

Bio-adrenomedullin (Bio-ADM) may assist in selecting acute dyspnoea patients for neurohormonal blockade

29 June 2021 (08:00 - 23:59)
Organised by:
Congress Presentation Part of: ePoster session Biomarkers HFA Premium Access Heart Failure 2021

About the speaker

Photo
Mr Zygimantas Abramikas

Vilnius University Hospital Santaros Clinics, Vilnius (Lithuania)

738 More presentations in this session

Presentation thumbnail
Atrial lead insertion during cardiac implantable electronic devices implantation in patients with atrial arrhythmia on hospital admission, when does the struggle for sinus rhythm make sense?
Assistant Professor N. Radovanovic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Features of the remodeling of atria and pulmonary veins in CHF patients with paroxysmal AF and permanent AF
Assistant Professor V. Kirillova (Ekaterinburg, RU)
Abstract Slides
Presentation thumbnail
Rhythm control versus rate control in patients with atrial fibrillation and heart failure across the left ventricular ejection fraction spectrum
Doctor D. Moysidis (Zurich, CH)
Abstract Slides
Presentation thumbnail
Impact of cardiac contractility modulation on ventricular rhythm and conduction disorders in patients with heart failure with reduced ejection fraction and various forms of atrial fibrillation
Doctor A. Safiullina (Moscow, RU)
Abstract Slides
Presentation thumbnail
Was a difference between late and early new-onset of atrial fibrillation in non st-elevation myocardial infarction?
Doctor H. Santos (Lisboa, PT)
Abstract Slides

Access the full session

Session thumbnail
ePoster session

The Event

Event poster

Heart Failure 2021

29 June 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Bio-adrenomedullin (Bio-ADM) a novel biomarker of peripheral, pulmonary and intravascular congestion
1 July 2021
thumbnail
Congress Presentation
Is there still a role for neurohormonal therapy in patients with STEMI and mildly reduced ejection
22 May 2023
thumbnail
Congress Presentation
Cardiac troponin t (cTnT) and n-terminal pro-B-type natriuretic peptides (NT-proBNP) for prediction of 30-day readmission or death in patients with acute dyspnea: data from the ACE2 study
20 May 2023
thumbnail
Congress Presentation
Angiotensin receptor-neprilysin inhibition in patients with de novo acute decompensated heart failure: a prespecified subgroup analysis of the PIONEER-HF trial
1 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources